SELLAS Life Sciences (SLS) Assets Average (2011 - 2026)

SELLAS Life Sciences (SLS) has 16 years of Assets Average data on file, last reported at $96.3 million in Q1 2026.

• Assets Average for Q1 2026 came in at $96.3 million, up 253.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $96.3 million (up 253.98% YoY), and the FY2025 annual result was $48.9 million, up 281.18% from the prior year.
• Assets Average grew to $96.3 million in Q1 2026 per SLS's latest filing, from $65.0 million in the prior quarter.
• Over five years, Assets Average peaked at $96.3 million in Q1 2026 and troughed at $7.2 million in Q4 2023.
• A 5-year average of $30.3 million and a median of $23.9 million in 2022 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2026: Assets Average plunged 69.53% in 2023, then surged 253.98% in 2026.
• A 5-year view of Assets Average shows it stood at $23.5 million in 2022, then sank by 69.53% to $7.2 million in 2023, then jumped by 221.13% to $23.0 million in 2024, then jumped by 182.78% to $65.0 million in 2025, then soared by 48.21% to $96.3 million in 2026.
• Business Quant data shows SLS's Assets Average at $96.3 million in Q1 2026, $65.0 million in Q4 2025, and $41.9 million in Q3 2025.